The new normal created by the recent COVID-19 pandemic has created disruptions in many sectors of life sciences. In the case of vaccine development, pairing SIA with digital twin modeling can provide invaluable insight into whether your equipment has the necessary capabilities to accept the process.DOWNLOAD ARTICLE
Pharmatech’s Mary Lou Zett has mapped out the planning process for the development of a biosimilar from an analytical approach supported by nonclinical and clinical comparability studies, in a two-part series in BioProcess Online. In part one, she details the biosimilar development path. Part two discusses how to prepare for your meetings with the FDA.DOWNLOAD ARTICLE
Pharmatech’s Mary Lou Zett has mapped out the planning process for the development of a biosimilar from an analytical approach supported by nonclinical and clinical comparability studies, in a two-part article in BioProcess Online.
In part one, she details the biosimilar development path. In the second part of the article discusses what–and when–to present research findings and how to prepare for your meetings with the FDA.DOWNLOAD ARTICLE
In the CPhI Annual Report for 2020, Bikash Chatterjee, CEO of Pharmatech Associates, said the concept of patient centricity has gone beyond being a buzzword to being a core value and that telemedicine will have a long-lasting impact. Chatterjee also foresees the industry will see voice collection of data in the home begin to be incorporated into both home and health settings.DOWNLOAD ARTICLE
We are deeply saddened to announce the unexpected passing of Warren G. Baker, CEO of Pharmatech Associates. While we mourn the passing of an inspriational leader, a succession plan was in place and announce the appointment of Mr. Bikash Chatterjee as CEO.DOWNLOAD ARTICLE
What The DMF?! Industry and FDA
Ultimately, the change of oversight from CDER to CBER will affect all past, present, and future biologic-related master files and marketing applications/approvals. It will be interesting to observe how much CBER will honor past CDER reviews and approvals, and how much sponsors will have to re-defend already approved submissions and regulatory strategies.
Jennifer Markarian interviewed Bikash Chatterjee for Pharmaceutical Technology’s June 2020 Equipment and Processing Report:
Manufacturers are adapting with virtual work, remote monitoring, and re-evaluation of facility design to ensure worker safety.
Bikash Chatterjee and Adam Lambert of Pharmatech Associates weigh in with fellow industry experts on developing and manufacturing controlled release products, in the latest issue of American Pharmaceutical Review.DOWNLOAD ARTICLE
“People tend to think of continuous manufacturing as something that you have to do only on a large-scale, with metric tons of material, but the reality is you can do it at small scale and have exquisite control” – Bikash Chatterjee, Pharmatech AssociatesDOWNLOAD ARTICLE
In an article in Outsourced Pharma, Bikash Chatterjee writes that understanding the FDA’s expectations will allow drug sponsors to make the most of available data derived during the emergency use authorization (EUA) and position them for a smoother regulatory process.DOWNLOAD ARTICLE